Literature DB >> 34244887

Atiprimod triggered apoptotic cell death via acting on PERK/eIF2α/ATF4/CHOP and STAT3/NF-ΚB axis in MDA-MB-231 and MDA-MB-468 breast cancer cells.

Ajda Coker-Gurkan1, Esin Can2, Semanur Sahin2, Pınar Obakan-Yerlikaya3, Elif-Damla Arisan4.   

Abstract

PURPOSE: The constitutive activation of STAT3 through receptor tyrosine kinases triggered breast cancer cell growth and invasion-metastasis. Atiprimod impacts anti-proliferative, anti-carcinogenic effects in hepatocellular carcinoma, lymphoma, multiple myeloma via hindering the biological activity of STAT3. Dose-dependent atiprimod evokes first autophagy as a survival mechanism and then apoptosis due to prolonged ER stress in pituitary adenoma cells. The therapeutic efficiency and mechanistic action of atiprimod in breast cancer cells have not been investigated yet. Thus, we aimed to modulate the pivotal role of ER stress in atiprimod-triggered apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells.
RESULTS: Dose- and time-dependent atiprimod treatment inhibits cell viability and colony formation in MDA-MB-468 and MDA-MB-231 breast cancer cells. A moderate dose of atiprimod (2 μM) inhibited STAT3 phosphorylation at Tyr705 residue and also suppressed the total expression level of p65. In addition, nuclear localization of STAT1, 3, and NF-κB was prevented by atiprimod exposure in MDA-MB-231 and MDA-MB-468 cells. Atiprimod evokes PERK, BiP, ATF-4, CHOP upregulation, and PERK (Thr980), eIF2α (Ser51) phosphorylation's. However, atiprimod suppressed IRE1α-mediated Atg-3, 5, 7, 12 protein expressions and no alteration was observed on Beclin-1, p62 expression levels. PERK/eIF2α/ATF4/CHOP axis pivotal role in atiprimod-mediated G1/S arrest and apoptosis via Bak, Bax, Bim, and PUMA upregulation in MDA-MB-468 cells. Moreover, atiprimod renders MDA-MB-231 more vulnerable to type I programmed cell death by plasmid-mediated increased STAT3 expression.
CONCLUSION: Atiprimod induced prolonged ER stress-mediated apoptosis via both activating PERK/eIF2α/ATF4/CHOP axis and suppressing STAT3/NF-κB transcription factors nuclear migration in TBNC cells.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Apoptosis; Atiprimod; Autophagy; Cancer; Cell cycle; Endoplasmic reticulum

Mesh:

Substances:

Year:  2021        PMID: 34244887     DOI: 10.1007/s11033-021-06528-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  37 in total

Review 1.  Stat proteins and oncogenesis.

Authors:  Jacqueline Bromberg
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  A new small-molecule Stat3 inhibitor.

Authors:  John S McMurray
Journal:  Chem Biol       Date:  2006-11

Review 3.  State of art of advanced triple negative breast cancer.

Authors:  Parham Khosravi-Shahi; Luis Cabezón-Gutiérrez; Maria Inmaculada Aparicio Salcedo
Journal:  Breast J       Date:  2019-06-02       Impact factor: 2.431

4.  Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice.

Authors:  A M Badger; J A Handler; C A Genell; D Herzyk; E Gore; R Polsky; L Webb; P J Bugelski
Journal:  Int J Immunopharmacol       Date:  1999-03

5.  Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo.

Authors:  Chakrabhavi Dhananjaya Mohan; Hanumantharayappa Bharathkumar; Krishna C Bulusu; Vijay Pandey; Shobith Rangappa; Julian E Fuchs; Muthu K Shanmugam; Xiaoyun Dai; Feng Li; Amudha Deivasigamani; Kam M Hui; Alan Prem Kumar; Peter E Lobie; Andreas Bender; Gautam Sethi; Kanchugarakoppal S Rangappa
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

6.  Stability of the recombinant anti‑erbB2 scFv‑Fc‑interleukin‑2 fusion protein and its inhibition of HER2‑overexpressing tumor cells.

Authors:  Yu-Jia Du; Ze-Min Lin; Ying-Hua Zhao; Xiu-Ping Feng; Chang-Qing Wang; Gang Wang; Chun-Di Wang; Wei Shi; Jian-Ping Zuo; Fan Li; Cheng-Zhong Wang
Journal:  Int J Oncol       Date:  2012-12-20       Impact factor: 5.650

7.  Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.

Authors:  Lorenzo Melchor; Emiliano Honrado; Jia Huang; Sara Alvarez; Tara L Naylor; María J García; Ana Osorio; David Blesa; Michael R Stratton; Barbara L Weber; Juan C Cigudosa; Nazneen Rahman; Katherine L Nathanson; Javier Benítez
Journal:  Clin Cancer Res       Date:  2007-12-15       Impact factor: 12.531

8.  Deregulation of RB1 expression by loss of imprinting in human hepatocellular carcinoma.

Authors:  Sumadi Lukman Anwar; Till Krech; Britta Hasemeier; Elisa Schipper; Nora Schweitzer; Arndt Vogel; Hans Kreipe; Ulrich Lehmann
Journal:  J Pathol       Date:  2014-06-16       Impact factor: 7.996

Review 9.  Breast cancer risk factors.

Authors:  Marzena Kamińska; Tomasz Ciszewski; Karolina Łopacka-Szatan; Paweł Miotła; Elżbieta Starosławska
Journal:  Prz Menopauzalny       Date:  2015-09-30

10.  Characterization of the complete chloroplast genome sequence of Dalbergia species and its phylogenetic implications.

Authors:  Yun Song; Yongjiang Zhang; Jin Xu; Weimin Li; MingFu Li
Journal:  Sci Rep       Date:  2019-12-31       Impact factor: 4.379

View more
  2 in total

Review 1.  Advances in Immunosuppressive Agents Based on Signal Pathway.

Authors:  Zhiqing Xu; Ming Chu
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

2.  Dexmetomidine promotes the activity of breast cancer cells through miR-199a/HIF-1α axis.

Authors:  Gang Wen; Naixing Xin
Journal:  Transl Cancer Res       Date:  2021-11       Impact factor: 1.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.